Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic adult Fabry disease patients, age 18-60 years~  1. Males: Plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than 30% mean normal levels and one or more of the characteristic features of Fabry disease~     i. neuropathic pain~     ii. cornea verticillata~     iii. clustered angiokeratoma~ 2. Females:~     a. historical genetic test results consistent with Fabry pathogenic mutation and one or more of the described characteristic features of Fabry disease:~     i. neuropathic pain~     ii. cornea verticillata~     iii. clustered angiokeratoma~     b. or in the case of novel mutations a first degree male family member with Fabry disease with the same mutation, and one or more of the characteristic features of Fabry disease~     i. neuropathic pain~     ii. cornea verticillata~     iii. clustered angiokeratoma~* Screening eGFR by CKD-EPI equation 40 to 120 mL/min/1.73 m²~* Linear negative slope of eGFR based on at least 3 serum creatinine values over approximately 1 year (range of 9 to 18 months, including the value obtained at the screening visit) of ≥ 2 mL/min/1.73 m²/year~* Treatment with a dose of 1 mg/kg agalsidase beta per infusion every 2 weeks for at least one year and at least 80% of 13 (10.4) mg/kg total dose over the last 6 months.~* Female patients and male patients whose co-partners are of child-bearing potential agree to use a medically accepted method of contraception, not including the rhythm method.~Exclusion Criteria:~* History of anaphylaxis or Type 1 hypersensitivity reaction to agalsidase beta~* Known non-pathogenic Fabry mutations~* History of renal dialysis or transplantation~* History of acute kidney injury in the 12 months prior to screening, including specific kidney diseases (e.g., acute interstitial nephritis, acute glomerular and vasculitic renal diseases); non-specific conditions (e.g, ischemia, toxic injury); as well as extrarenal pathology (e.g., prerenal azotemia, and acute postrenal obstructive nephropathy)~* Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy initiated or dose changed in the 4 weeks prior to screening~* Patient with a screening eGFR value between 91-120 mL/min/1.73 m², having an historical eGFR value higher than 120 mL/min/1.73 m² (during 9 to 18 months before screening)~* Urine protein to creatinine ratio (UPCR) \> 0.5 g/g and not treated with an ACE inhibitor or ARB~* Cardiovascular event (myocardial infarction, unstable angina) in the 6 month period before randomization~* Congestive heart failure NYHA Class IV~* Cerebrovascular event (stroke, transient ischemic attack) in the 6 month period before randomization~* Known history of hypersensitivity to Gadolinium contrast agent that is not managed by the use of pre-medication~* Female subjects who are pregnant, planning to become pregnant during the study, or are breastfeeding~* Presence of any medical, emotional, behavioral or psychological condition that, in the judgment of the Investigator and/or Medical Director, would interfere with the patient's compliance with the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PRX-102 (pegunigalsidase alfa) (Type: EXPERIMENTAL): PRX-102 infusion every 2 weeks
- agalsidase beta (Type: ACTIVE_COMPARATOR): agalsidase beta infusion every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).